680610-54-2

Upstream product

• 115029-22-6 2-fluoro-3-(trifluoromethyl)benzoic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 208173-19-7 2-fluoro-3-trifluoromethylbenzoyl chloride 

Downstream Products

• 854778-39-5 [2-fluoro-3-(trifluoro-methyl)phenyl](3-methoxyphenyl)methanone 
• 1085267-45-3 (2-fluoro-3-(trifluoromethyl)phenyl)(4-chlorophenyl)methanone 
• 875795-91-8 (2-fluoro-3-(trifluoromethyl)phenyl)(4-fluorophenyl)methanone 
• 1227290-31-4 3,4-dimethoxyphenyl[(2-fluoro-3-(trifluoromethyl)phenyl)]methanone 
• 680610-69-9 2,4-dimethoxyphenyl[(2-fluoro-3-(trifluoromethyl)phenyl)]methanone 
• 680611-18-1 3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole 
• 1227290-32-5 3-(3,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole 
• 1173793-72-0 2-fluoro-[3-(trifluoromethyl)phenyl](1-methyl-1H-tetrazol-5-yl)methanone 
• 908566-32-5 1-[2-fluoro-3-(trifluoromethyl)phenyl]-3-phenylpropan-1-one 
• 1026186-75-3 1-benzyl-3-(4-methoxy-phenyl)-7-trifluoromethyl-1H-indazole 
• 1027887-95-1 2-[3-(4-methoxy-phenyl)-7-trifluoromethyl-indazol-1-yl]-ethanol 
• 680611-14-7 3-(4-methoxy-phenyl)-7-trifluoromethyl-1H-indazole 
• 680610-53-1 (2-fluoro-3-trifluoromethyl-phenyl)-(4-methoxy-phenyl)-methanone 

Relevant academic research and scientific papers

TETRAZOLINONE COMPOUND AND USE THEREOF

The compound represented by formula (1): wherein R4 and R5 each represents a hydrogen atom, a halogen atom, or a C1-C3 alkyl group; R6 represents a C1-C4 alkyl group, a C3-C6 cycloalkyl group, or the like; R7, R8, and R9 each represents a hydrogen atom, a halogen atom, or the like; R10 represents a C1-C3 alkyl group, or the like; R13 represents a C1-C3 alkyl group, or the like; and Q represents a phenyl group, or the like; has an excellent control effect on pests.

FUNGICIDE HYDROXIMOYL-TETRAZOLE DERIVATIVES

The present invention relates to hydroximoyl-tetrazole derivatives, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.

Development of a selective modulator of aryl hydrocarbon (Ah) receptor activity that exhibits anti-inflammatory properties

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. However, the role of the AHR in normal physiology is still an area of intense investigation. For example, thi

Biarylether amide quinolines as liver X receptor agonists

A series of 4-(amido-biarylether)-quinolines was prepared as potential LXR agonists. Appropriate substitution with amide groups provided high affinity LXR ligands, some with excellent potency and efficacy in functional assays of LXR activity. Novel amide

Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRβ

A series of cinnolines/quinolines was prepared and it was found that 4-phenyl-cinnoline/quinolines with either a 2′,3′ or 2′,5′-disubstituted benzyloxy moiety or the 1-Me-7-indole methoxy moiety on the meta position of the 4-phenyl ring showed good binding selectivity for LXRβ over LXRα. The LXRβ binding selective modulators displayed good activity for inducing ABCA1 gene expression in J774 macrophage cell line and poor efficacy in the LXRα Gal4 functional assay. 26, 37 and 41 were examined for their ability to induce SREBP-1c gene expression in Huh-7 liver cell line and they were weak partial agonists.

Indazole-based Liver X Receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis

A series of substituted 2-benzyl-3-aryl-7-trifluoromethylindazoles were prepared as LXR modulators. These compounds were partial agonists in transactivation assays when compared to 1 (T0901317) and were slightly weaker with respect to potency and efficacy on LXRα than on LXRβ. Lead compounds in this series 12 (WAY-252623) and 13 (WAY-214950) showed less lipid accumulation in HepG2 cells than potent full agonists 1 and 3 (WAY-254011) but were comparable in efficacy to 1 and 3 with respect to cholesterol efflux in THP-1 foam cells, albeit weaker in potency. Compound 13 reduced aortic lesion area in LDLR knockout mice equivalently to 3 or positive control 2 (GW3965). In a 7-day hamster model, compound 13 showed a lesser propensity for plasma TG elevation than 3, when the compounds were compared at doses in which they elevated ABCA1 and ABCG1 gene expression in duodenum and liver at equal levels. In contrast to results previously published for 2, the lack of TG effect of 13 correlated with its inability to increase liver fatty acid synthase (FAS) gene expression, which was up-regulated 4-fold by 3. These results suggest indazoles such as 13 may have an improved profile for potential use as a therapeutic agent.

SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES

This invention provides compound of formulae I or II having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined in the specification or a pharmaceutically acceptable salt thereof which are useful for the treatment of the infla